Clinical Controlled Study on the Efficacy of Denosumab in Treating Osteoporosis in the Domestic Population and Its Impact on Sarcopenia-related Outcomes

Through the method of a clinical randomized controlled trial, patients meeting the study criteria are randomly assigned to either the Denosumab treatment group or a placebo group. After a treatment period of 12 months, the differences in osteoporosis and sarcopenia-related baseline assessment changes between the two groups are compared. This is to explore the effect of Denosumab in treating osteoporosis and its impact on sarcopenia. The goal is to evaluate the efficacy of Denosumab in treating osteoporosis in the domestic population and its related impact on sarcopenia, with the aim of providing an effective treatment option for the domestic population suffering from 'osteoporosis-sarcopenia syndrome.

Study Overview

• Status: Recruiting
• Conditions: Sarcopenia; Osteoporosis; Denosumab
• Intervention / Treatment: Drug: Denosumab Injection; Other: Normal saline injection (1.0ml/ branch)

• Study Type: Interventional
• Enrollment (Estimated): 86
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: Wen Peng; Phone Number: 13986074846; Email: pengwen666@sina.com
• Study Contact Backup: Name: ShaoTian Li; Phone Number: 18300850090; Email: 1398998676@qq.com

Study Locations

• China
  • Hubei
    • Wuhan, Hubei, China, 430022
      • Recruiting
      • Union Hospital Tongji Medical College Huazhong University of Science and Technology
      • Contact: Wen Peng; Phone Number: 13986074846; Email: pengwen666@sina.com
      • Contact: ShaoTian Li; Phone Number: 18300850090; Email: 1398998676@qq.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Clinical diagnosis of postmenopausal/senile osteoporosis after examination and assessment.
• Clinical diagnosis of postmenopausal/senile osteoporosis combined with sarcopenia after examination and assessment.
• Have not previously taken any other anti-osteoporosis drugs.

Exclusion Criteria:

• Clinical diagnosis of pathological fractures.
• Have participated in another clinical trial within the past 3 months or have taken other anti-osteoporosis drugs within the past 6 months.
• Severe chronic metabolic diseases or serious organ failure.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Denosumab Group; Denosumab injection 60mg (1.0ml/ branch, Jiangsu Taikang Biological Medicine Co., LTD., s20233111), once every 6 months, 60mg, subcutaneous injection, at the same time to supplement calcium and vitamin D.	Drug: Denosumab Injection; Denosumab injection 60mg (1.0ml/ branch, Jiangsu Taikang Biological Medicine Co., LTD., s20233111), once every 6 months, 60mg, subcutaneous injection, at the same time to supplement calcium and vitamin D.
Placebo Comparator: Placebo Group; Placebo drug, the main component of normal saline injection (1.0ml/ dose). In addition to the different production batch number, its appearance, character, specification, administration mode and frequency are exactly the same as the experimental group of drugs (different production batch number is convenient for later unblinding reference). Take calcium and vitamin D supplements. The study lasted for 12 months.	Other: Normal saline injection (1.0ml/ branch); Placebo drug, the main component of normal saline injection (1.0ml/ dose). In addition to the different production batch number, its appearance, character, specification, administration mode and frequency are exactly the same as the experimental group of drugs (different production batch number is convenient for later unblinding reference). Take calcium and vitamin D supplements.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Osteoporosis-related Primary Outcome	Bone mineral density (BMD) changed from baseline after 6 and 12 months of treatment in both groups. (DXA method, T value has no specific unit of measure) Bone transformation markers (BTM) changed from baseline after 6 and 12 months of treatment in both groups. (Total P1NP（ng/ml）, total 25 hydroxyvitamin D（nmol/L）, osteocalcin N-terminal fragment（ng/ml）, βCrossLap（pg/ml）) After 6 and 12 months of treatment, osteoporosis related blood biochemistry(TBIL, DBIL, Cr, UA, HCY in umol/L, BUN, TC, TG, HDL, LDL, Ca, IP in mmol/L, ALB, PAB in g/L, CK, ALT, AST, GGT in U/L), blood routine(WBC, PLT, NEU, LYMPH, MONO, EOS in G/L, RBC in T/L, HGB in g/L), inflammatory indicators(IL-1β, TNF-α, IL-6 in pg/mL), and related hormones(PTH, CT in ng/L) changed from baseline. Changes in the above indicators from the baseline are possible or hypothetical, and all are subject to experimental results.	1 year
Sarcopenia-related Primary Outcome	After 6 and 12 months of treatment, the SARC-F scale was evaluated compared with baseline.(No unit of measure) After 6 and 12 months of treatment, muscle strength (dominant hand grip strength, Kg) changed from baseline in both groups. After 6 and 12 months of treatment, skeletal muscle mass (ASM in Kg), skeletal muscle mass index (ASM and height will be combined to report ASMI in Kg/m²), body fat percentage（%） and limb fat percentage（%）in both groups were changed from baseline. (BIA method) After 6 and 12 months of treatment, the walking speed of 6 M（m/s） and the sitting time of 5 times(s) were changed from baseline. Changes in the above indicators from the baseline are possible or hypothetical, and all are subject to experimental results.	1 year

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Quality of life and fall risk	Changes in quality of life and fall risk from baseline were assessed using the abbreviated Health Survey Form (SF-36) and the Morse Fall Risk Assessment Scale at the end of 12 months of treatment in both groups.(The score has no specific unit of measure) Changes in the above scale from the baseline are possible or hypothetical, and all are subject to experimental results.	1 year

Collaborators and Investigators

• Sponsor: Wuhan Union Hospital, China

Study record dates

Study Major Dates

• Study Start (Actual): February 1, 2024
• Primary Completion (Estimated): December 31, 2024
• Study Completion (Estimated): March 1, 2025

Study Registration Dates

• First Submitted: November 10, 2023
• First Submitted That Met QC Criteria: November 23, 2023
• First Posted (Actual): December 4, 2023

Study Record Updates

• Last Update Posted (Actual): August 16, 2024
• Last Update Submitted That Met QC Criteria: August 15, 2024
• Last Verified: November 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Metabolic Diseases; Nervous System Diseases; Neurologic Manifestations; Musculoskeletal Diseases; Neuromuscular Manifestations; Pathological Conditions, Anatomical; Bone Diseases; Muscular Atrophy; Atrophy; Bone Diseases, Metabolic; Sarcopenia; Osteoporosis; Physiological Effects of Drugs; Bone Density Conservation Agents; Denosumab
• Other Study ID Numbers: UHCT230847

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No